Cilazapril

Source: Wikipedia, the free encyclopedia.
Cilazapril
Kekulé, stereo, skeletal formula of cilazapril ((1S,9S)-9-[(2S)-2-yl]amin,-1-carbox)
Names
Preferred IUPAC name
(1S,9S)-9-{[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
Identifiers
3D model (
JSmol
)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard
100.168.764 Edit this at Wikidata
IUPHAR/BPS
KEGG
UNII
  • InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28) ☒N
    Key: HHHKFGXWKKUNCY-UHFFFAOYSA-N ☒N
  • CCOC(=O)C(CCc1ccccc1)NC1CCCN2CCCC(N2C1=O)C(O)=O
Properties
C22H31N3O5
Molar mass 417.506 g·mol−1
log P 2.212
Acidity (pKa) 2.285
Basicity (pKb) 11.712
Pharmacology
C09AA08 (WHO)
Oral
Legal status
  • UK: POM (Prescription only)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Cilazapril is an

congestive heart failure.[1][2]

It was patented in 1982 and approved for medical use in 1990.[3]

Chemistry

Of the eight possible

stereoisomers, only the all-(S)-form is medically viable.[citation needed
]

Brand names

It is branded as Dynorm, Inhibace, Vascace and many other names in various countries. None of these are available in the United States as of May 2010.[4]

References